ERBB2 and cancer: Although targeting this immune escape mechanism with ICIs has proven beneficial in other cancers, these treatments have regrettably shown limited effectiveness in patients with TNBC and HER2+ subtypes, as evidenced by clinical trials (7, 13–15).